Developed through a strategic collaboration between

partner-1 Logo 3

The MENA Thalassemia Experience

Apply Now
  • Friday, 30 October 2026 | 16:00 - 19:30 GST
  • Saturday, 31 October 2026 | 13:00 - 16:15 GST
  • CME
  • Virtual

Overview

Despite regional challenges, our commitment to your continuous education on thalassemia management remains absolute. To maximize live interaction, this virtual masterclass begins with six mandatory, on-demand foundation modules to review at your own pace. This clears the way for an immersive live broadcast streaming from the London Hub, designed to make you feel as though you are in the same room as the expert speakers.

Day 1 launches with interactive patient journeys where your real-time insights and questions shape the analysis, followed by a highly focused fellows clinical forum.

Day 2 transitions into targeted, small-group expert breakouts, a regional prevention program discussion, and a collaborative, peer-led session on integrating novel therapies into localized practice. This virtual architecture elevates your daily practice and transforms patient care.

Apply Now

Faculty

Speaker Image
Nica Cappellini, MD
Co-Chair / Course Director

Professor

Department of Internal Medicine

University of Milan-Italy

Director

Internal Medicine Unit Milan Hospital

Milan, Italy

Speaker Image
Ali Taher, MD, PhD, FRCP
Co-Chair / Course Director

Professor of Medicine

Department of Internal Medicine

American University of Beirut Medical Center

Beirut, Lebanon

Speaker Image
Khaled M. Musallam, MD, PhD
PANELIST

Group Chief Research Officer (Burjeel Holdings)

Deputy CEO and Chief of Cell & Gene Therapy and Hematology

Director of Thalassemia & Sickle Cell Center and Center for Research on Rare Blood Disorders (CR-RBD)

Burjeel Cancer Institute

Burjeel Medical City

Abu Dhabi, United Arab Emirates

Speaker Image
Sujit Sheth, MD
PANELIST

Harold Weill Professor of Pediatrics

Chief, Division of Pediatric Hematology and Oncology

Department of Pediatrics

Weill Cornell Medicine

New York, New York, United States

Agenda

Day 1

16:00

Welcome and Introductions

16:20

Interactive Thalassemia Patient Journeys

16:50

Screen Break

17:00

Thalassemia Patient Journeys: Faculty Panel & Insights

17:30

Mid-Session Break (Maghrib Prayer)

18:00

Your Cases Examined: Fellows Clinical Forum

19:15

Wrap-Up of Day 1 and Overview of Day 2

Day 2

13:00

Expert Clinical Forum: Meeting Evolving Patient Needs

13:30

From Strategy to Impact: Thalassemia Prevention Programs

14:00

Meet the Patient: Perspectives and Realities

14:30

Screen Break

14:45

Novel Therapies in Clinical Practice

15:30

Key Takeaways and Session Summaries

16:00

Final Words and Evaluation

Program Information

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

APPLICATION SUBMISSION

Applicants are requested to complete the survey. Following the application submission, Medscape will review responses and will notify you of acceptance. We aim to create a diverse and inclusive environment in line with our activity objectives.

Program Logo Program Logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 5.75 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text]

Contact persons: In case of any questions, please contact:
Hilda Hansen – hhansen@medscapelive.com


Learning Objectives

[title]Upon completion of this activity, participants will:[/title] [para] Have increased knowledge regarding the [/para] [LIST][ITEM] Primary drivers of morbidity/mortality in thalassemias, based on the pathophysiology [ITEM] Burden of thalassemia for different types of patients [ITEM] Evolving needs of patients with thalassemia as they survive longer [ITEM] Role of novel therapies for transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT)[/LIST] [break] [para] Have greater competence related to [/para] [LIST][ITEM] Implementing novel therapeutic approaches for patients with thalassemia into practice [ITEM] Managing iron overload to prevent organ toxicity [ITEM] Transitioning patients with thalassemia from pediatric to adult care settings [ITEM] Implementing comprehensive thalassemia prevention strategies [/LIST] [break] [para] Demonstrate greater confidence in their ability to [/para] [LIST][ITEM] Incorporate the latest advances into the therapeutic management of patients with thalassemia [/LIST]

Goal Statement

The goal of this activity is for learners to be better able to implement optimal diagnostic and management strategies for patients with thalassemias in clinical practice.

Target Audience

[para]This educational activity is intended for an audience of physicians involved in the management of thalassemia based in the Middle East and North Africa.[/para]

Supported by independent educational grants from Agios, Bristol Myers Squibb, NewBridge Pharmaceuticals, and Vertex.
Manage Preferences Your Privacy Choices